Category Business

Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma

Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma The National Medical Products Administration (NMPA) of China has granted approval for Sarclisa (isatuximab), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult…

Read MoreSarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma

Pharma Partners Gilead and LEO Pharma to Accelerate Oral STAT6 Program for Inflammatory Diseases

Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership designed to accelerate the development and commercialization of LEO Pharma’s…

Read MorePharma Partners Gilead and LEO Pharma to Accelerate Oral STAT6 Program for Inflammatory Diseases

Alnylam Strongly Reports Q4 2024 Revenues, 2025 Revenue Guidance, and Ambitious Pipeline Goals

Alnylam Pharmaceuticals Reports Preliminary 2024 Financials, 2025 Revenue and Pipeline Guidance Alnylam Pharmaceuticals Reports a global leader in RNA interference (RNAi) therapeutics, today released preliminary financial results for the fourth quarter and full year 2024, alongside its guidance for 2025…

Read MoreAlnylam Strongly Reports Q4 2024 Revenues, 2025 Revenue Guidance, and Ambitious Pipeline Goals